No Data
No Data
Express News | Viridian Therapeutics Inc - Enters $300 Million Sale Agreement With Jefferies
Viridian Therapeutics Faces Uncertainty Amid Regulatory Approval Challenges
Viridian Therapeutics | 10-K: FY2024 Annual Report
H.C. Wainwright Maintains Viridian Therapeutics(VRDN.US) With Buy Rating, Maintains Target Price $34
RBC Capital Adjusts Viridian Therapeutics Price Target to $46 From $47, Maintains Outperform - Speculative Risk Rating
A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $27 to $46